INT119421

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2004
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 6.94
Pain Relevance 3.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (RAF1) cytoplasm (RAF1) cytosol (RAF1)
cell proliferation (RAF1) signal transduction (RAF1) nucleus (RAF1)
Anatomy Link Frequency
urinary bladder 1
brains 1
RAF1 (Homo sapiens)
Pain Link Frequency Relevance Heat
opioid receptor 5 99.60 Very High Very High Very High
Morphine 10 99.00 Very High Very High Very High
narcan 2 98.40 Very High Very High Very High
Lasting pain 2 97.80 Very High Very High Very High
Kinase C 5 96.48 Very High Very High Very High
Analgesic 4 95.96 Very High Very High Very High
tolerance 5 95.56 Very High Very High Very High
addiction 3 93.16 High High
MU agonist 2 92.80 High High
opiate 7 92.76 High High
Disease Link Frequency Relevance Heat
Apoptosis 231 98.72 Very High Very High Very High
Carcinoma 195 98.48 Very High Very High Very High
Urological Neuroanatomy 3 97.96 Very High Very High Very High
Pain 8 97.80 Very High Very High Very High
Thyroid Disease 3 96.68 Very High Very High Very High
Transitional Cell Carcinoma 1 95.68 Very High Very High Very High
Gastrointestinal Stromal Tumor 3 95.64 Very High Very High Very High
Renal Cell Carcinoma 19 94.20 High High
Renal Cancer 2 93.52 High High
Opiate Addiction 3 93.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We found that pretreatment of CHO cells stably expressing the human micro-opioid receptor with the selective Raf-1 inhibitor, 3-(3,5-dibromo-4-hydroxybenzylidene)-5-iodo-1,3-dihydroindol-2-one (GW5074, 10 microM, 60 min) completely abolished chronic morphine-mediated AC superactivation (P < 0.01).
Negative_regulation (inhibitor) of Raf-1 associated with opioid receptor and morphine
1) Confidence 0.41 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16750187 Disease Relevance 0.08 Pain Relevance 0.92
Chronic morphine-mediated adenylyl cyclase superactivation is attenuated by the Raf-1 inhibitor, GW5074.
Negative_regulation (inhibitor) of Raf-1 associated with narcan and morphine
2) Confidence 0.41 Published 2006 Journal Eur. J. Pharmacol. Section Title Doc Link 16750187 Disease Relevance 0.10 Pain Relevance 1.00
Inhibition of Raf1 modestly inhibited the magnitude of D2L receptor-induced sensitization of AC6; however, activation of PKC robustly enhanced D2L receptor-mediated AC6 sensitization in a Raf1-dependent manner.
Negative_regulation (Inhibition) of Raf1 associated with kinase c
3) Confidence 0.23 Published 2005 Journal Cell. Signal. Section Abstract Doc Link 15683739 Disease Relevance 0 Pain Relevance 0.40
In contrast, the components of MAPK cascade (Ras/c-Raf-1/MEK/ERK) were decreased in the same brains.
Negative_regulation (decreased) of c-Raf in brains
4) Confidence 0.18 Published 2004 Journal J. Neurochem. Section Abstract Doc Link 15198681 Disease Relevance 0.48 Pain Relevance 0.85
It was selected for further pharmacological characterization based on potent inhibition of Raf-1 and its favourable kinase selectivity profile.
Negative_regulation (inhibition) of Raf-1
5) Confidence 0.10 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.65 Pain Relevance 0
In preclinical animal models, cetuximab and other epidermal growth factor receptor antagonists have been shown to be synergistic with cisplatin56,57 and paclitaxel.58,59 In a preclinical study, the efficacy of combination of cetuximab and paclitaxel was evaluated for treating human transitional cell carcinoma (TCC) of the urinary bladder of nude mice.59 Paclitaxel demonstrated significant antitumor activity and the extent of paclitaxel-induced apoptosis was enhanced in the presence of reduced Raf-1 activity.60 Cetuximab downregulates Raf-1 activity, and presumably by this mechanism cetuximab enhances the antiproliferative and apoptotic effects of paclitaxel in a dose-dependent manner in vitro.
Negative_regulation (downregulates) of Raf-1 in urinary bladder associated with antagonist, apoptosis and transitional cell carcinoma
6) Confidence 0.08 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886327 Disease Relevance 0.74 Pain Relevance 0.05
It was originally developed as an inhibitor of Raf-1 which is vital for cell proliferation.
Negative_regulation (inhibitor) of Raf-1
7) Confidence 0.05 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895781 Disease Relevance 0.97 Pain Relevance 0.06
In addition, Mcl-1 downregulation also increased apoptosis rates after treatment with PI3K inhibitors and, to a lower extent, after treatment with mTOR, Raf I and VEGF/PDGF kinase inhibitors.
Negative_regulation (inhibitors) of Raf I associated with apoptosis
8) Confidence 0.01 Published 2006 Journal BMC Cancer Section Abstract Doc Link PMC1601962 Disease Relevance 1.43 Pain Relevance 0
Treatment of Huh7 cells with a Raf I-kinase inhibitor neither altered Mcl-1 expression nor influenced sensitivity towards chemotherapeutic drug-induced apoptosis (Fig. 2A, and data not shown).
Neg (neither) Negative_regulation (inhibitor) of Raf I associated with apoptosis
9) Confidence 0.01 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.00 Pain Relevance 0
Sorafenib (SOR) is an oral small molecule that predominantly inhibits the serine/threonine raf-1 kinase.
Negative_regulation (inhibits) of raf-1 kinase
10) Confidence 0.01 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 1.49 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox